Literature DB >> 32209459

Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity.

Sebastian Ols1, Lifei Yang2, Elizabeth A Thompson1, Pradeepa Pushparaj3, Karen Tran2, Frank Liang1, Ang Lin1, Bengt Eriksson4, Gunilla B Karlsson Hedestam3, Richard T Wyatt2, Karin Loré5.   

Abstract

Although intramuscular (i.m.) administration is the most commonly used route for licensed vaccines, subcutaneous (s.c.) delivery is being explored for several new vaccines under development. Here, we use rhesus macaques, physiologically relevant to humans, to identify the anatomical compartments and early immune processes engaged in the response to immunization via the two routes. Administration of fluorescently labeled HIV-1 envelope glycoprotein trimers displayed on liposomes enables visualization of targeted cells and tissues. Both s.c. and i.m. routes induce efficient immune cell infiltration, activation, and antigen uptake, functions that are tightly restricted to the skin and muscle, respectively. Antigen is also transported to different lymph nodes depending on route. However, these early differences do not translate into significant differences in the magnitude or quality of antigen-specific cellular and humoral responses over time. Thus, although some distinct immunological differences are noted, the choice of route may instead be motivated by clinical practicality.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B cell follicle; HIV envelope glycoprotein; antigen transport; dendritic cell; follicular dendritic cell; intramuscular; lymph node; monocytes; subcutaneous; vaccination

Mesh:

Substances:

Year:  2020        PMID: 32209459      PMCID: PMC7198771          DOI: 10.1016/j.celrep.2020.02.111

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  36 in total

1.  Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults.

Authors:  Ian F Cook; Ian Barr; Gunter Hartel; Dimity Pond; Alan W Hampson
Journal:  Vaccine       Date:  2005-12-13       Impact factor: 3.641

2.  Critical Role for Skin-Derived Migratory DCs and Langerhans Cells in TFH and GC Responses after Intradermal Immunization.

Authors:  Clément Levin; Olivia Bonduelle; Charles Nuttens; Charlotte Primard; Bernard Verrier; Alexandre Boissonnas; Béhazine Combadière
Journal:  J Invest Dermatol       Date:  2017-04-28       Impact factor: 8.551

Review 3.  From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity.

Authors:  Natalie L Trevaskis; Lisa M Kaminskas; Christopher J H Porter
Journal:  Nat Rev Drug Discov       Date:  2015-10-16       Impact factor: 84.694

4.  A simple and safe technique for longitudinal bone marrow aspiration in cynomolgus and rhesus macaques.

Authors:  Mats Spångberg; Paola Martinez; Helene Fredlund; Gunilla B Karlsson Hedestam; Christopher Sundling
Journal:  J Immunol Methods       Date:  2014-05-17       Impact factor: 2.303

5.  Covalent Linkage of HIV-1 Trimers to Synthetic Liposomes Elicits Improved B Cell and Antibody Responses.

Authors:  Shridhar Bale; Geraldine Goebrecht; Armando Stano; Richard Wilson; Takayuki Ota; Karen Tran; Jidnyasa Ingale; Michael B Zwick; Richard T Wyatt
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

6.  Dissociation of skeletal muscle for flow cytometric characterization of immune cells in macaques.

Authors:  Frank Liang; Aurélie Ploquin; Karin Loré; Nancy J Sullivan; José DelaO Hernández; Hugues Fausther-Bovendo; Gustaf Lindgren; Daphne Stanley; Aiala Salvador Martinez; Jason M Brenchley; Richard A Koup
Journal:  J Immunol Methods       Date:  2015-06-20       Impact factor: 2.303

7.  Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach.

Authors:  Paola Martinez-Murillo; Karen Tran; Javier Guenaga; Gustaf Lindgren; Monika Àdori; Yu Feng; Ganesh E Phad; Néstor Vázquez Bernat; Shridhar Bale; Jidnyasa Ingale; Viktoriya Dubrovskaya; Sijy O'Dell; Lotta Pramanik; Mats Spångberg; Martin Corcoran; Karin Loré; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

8.  Visualization of early events in mRNA vaccine delivery in non-human primates via PET-CT and near-infrared imaging.

Authors:  Kevin E Lindsay; Sushma M Bhosle; Chiara Zurla; Jared Beyersdorf; Kenneth A Rogers; Daryll Vanover; Peng Xiao; Mariluz Araínga; Lisa M Shirreff; Bruno Pitard; Patrick Baumhof; Francois Villinger; Philip J Santangelo
Journal:  Nat Biomed Eng       Date:  2019-04-01       Impact factor: 25.671

9.  Trans-nodal migration of resident dendritic cells into medullary interfollicular regions initiates immunity to influenza vaccine.

Authors:  Matthew C Woodruff; Balthasar A Heesters; Caroline N Herndon; Joanna R Groom; Paul G Thomas; Andrew D Luster; Shannon J Turley; Michael C Carroll
Journal:  J Exp Med       Date:  2014-07-21       Impact factor: 14.307

10.  Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches.

Authors:  Matthias Pauthner; Colin Havenar-Daughton; Devin Sok; Joseph P Nkolola; Raiza Bastidas; Archana V Boopathy; Diane G Carnathan; Abishek Chandrashekar; Kimberly M Cirelli; Christopher A Cottrell; Alexey M Eroshkin; Javier Guenaga; Kirti Kaushik; Daniel W Kulp; Jinyan Liu; Laura E McCoy; Aaron L Oom; Gabriel Ozorowski; Kai W Post; Shailendra K Sharma; Jon M Steichen; Steven W de Taeye; Talar Tokatlian; Alba Torrents de la Peña; Salvatore T Butera; Celia C LaBranche; David C Montefiori; Guido Silvestri; Ian A Wilson; Darrell J Irvine; Rogier W Sanders; William R Schief; Andrew B Ward; Richard T Wyatt; Dan H Barouch; Shane Crotty; Dennis R Burton
Journal:  Immunity       Date:  2017-06-20       Impact factor: 31.745

View more
  27 in total

1.  Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations.

Authors:  Jacob T Martin; Christopher A Cottrell; Aleksandar Antanasijevic; Diane G Carnathan; Benjamin J Cossette; Chiamaka A Enemuo; Etse H Gebru; Yury Choe; Federico Viviano; Stephanie Fischinger; Talar Tokatlian; Kimberly M Cirelli; George Ueda; Jeffrey Copps; Torben Schiffner; Sergey Menis; Galit Alter; William R Schief; Shane Crotty; Neil P King; David Baker; Guido Silvestri; Andrew B Ward; Darrell J Irvine
Journal:  NPJ Vaccines       Date:  2020-08-05       Impact factor: 7.344

2.  A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity.

Authors:  Murillo Silva; Yu Kato; Mariane B Melo; Ivy Phung; Brian L Freeman; Zhongming Li; Kangsan Roh; Jan W Van Wijnbergen; Hannah Watkins; Chiamaka A Enemuo; Brittany L Hartwell; Jason Y H Chang; Shuhao Xiao; Kristen A Rodrigues; Kimberly M Cirelli; Na Li; Sonya Haupt; Aereas Aung; Benjamin Cossette; Wuhbet Abraham; Swati Kataria; Raiza Bastidas; Jinal Bhiman; Caitlyn Linde; Nathaniel I Bloom; Bettina Groschel; Erik Georgeson; Nicole Phelps; Ayush Thomas; Julia Bals; Diane G Carnathan; Daniel Lingwood; Dennis R Burton; Galit Alter; Timothy P Padera; Angela M Belcher; William R Schief; Guido Silvestri; Ruth M Ruprecht; Shane Crotty; Darrell J Irvine
Journal:  Sci Immunol       Date:  2021-12-03

3.  Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant.

Authors:  Ning Yang; Aitor Garcia; Cindy Meyer; Thomas Tuschl; Taha Merghoub; Jedd D Wolchok; Liang Deng
Journal:  NPJ Vaccines       Date:  2022-10-19       Impact factor: 9.399

4.  The investigation of mRNA vaccines formulated in liposomes administrated in multiple routes against SARS-CoV-2.

Authors:  Hai Huang; Caili Zhang; Shuping Yang; Wen Xiao; Qian Zheng; Xiangrong Song
Journal:  J Control Release       Date:  2021-05-21       Impact factor: 9.776

5.  3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates.

Authors:  Sudhir Pai Kasturi; Mohammed Ata Ur Rasheed; Colin Havenar-Daughton; Mathew Pham; Traci Legere; Zarpheen Jinnah Sher; Yevgeny Kovalenkov; Sanjeev Gumber; Jessica Y Huang; Raphael Gottardo; William Fulp; Alicia Sato; Sheetal Sawant; Sherry Stanfield-Oakley; Nicole Yates; Celia LaBranche; S Munir Alam; Georgia Tomaras; Guido Ferrari; David Montefiori; Jens Wrammert; Francois Villinger; Mark Tomai; John Vasilakos; Christopher B Fox; Steven G Reed; Barton F Haynes; Shane Crotty; Rafi Ahmed; Bali Pulendran
Journal:  Sci Immunol       Date:  2020-06-19

Review 6.  Controlling timing and location in vaccines.

Authors:  Darrell J Irvine; Aereas Aung; Murillo Silva
Journal:  Adv Drug Deliv Rev       Date:  2020-06-26       Impact factor: 15.470

Review 7.  Delivery Routes for COVID-19 Vaccines.

Authors:  Jang Hyun Park; Heung Kyu Lee
Journal:  Vaccines (Basel)       Date:  2021-05-19

8.  Combined PET and whole-tissue imaging of lymphatic-targeting vaccines in non-human primates.

Authors:  Jacob T Martin; Brittany L Hartwell; Sidath C Kumarapperuma; Mariane B Melo; Diane G Carnathan; Benjamin J Cossette; Josetta Adams; Siqi Gong; Wei Zhang; Talar Tokatlian; Sergey Menis; Torben Schiffner; Crystal G Franklin; Beth Goins; Peter T Fox; Guido Silvestri; William R Schief; Ruth M Ruprecht; Darrell J Irvine
Journal:  Biomaterials       Date:  2021-05-14       Impact factor: 12.479

Review 9.  Predictive Markers of Immunogenicity and Efficacy for Human Vaccines.

Authors:  Matthieu Van Tilbeurgh; Katia Lemdani; Anne-Sophie Beignon; Catherine Chapon; Nicolas Tchitchek; Lina Cheraitia; Ernesto Marcos Lopez; Quentin Pascal; Roger Le Grand; Pauline Maisonnasse; Caroline Manet
Journal:  Vaccines (Basel)       Date:  2021-06-01

10.  Inadequate deltoid muscle penetration and concerns of improper COVID mRNA vaccine administration can be avoided by injection technique modification.

Authors:  Nimrod Rahamimov; Veronica Baturov; Adi Shani; Ilai Ben Zoor; Doron Fischer; Anna Chernihovsky
Journal:  Vaccine       Date:  2021-07-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.